This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Meridian Life Science® Successfully Manufactures Rhinovirus Challenge Stock

Stocks in this article: VIVO

Meridian Life Science, Inc., (MLS) of Memphis, Tennessee, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO), recently completed the manufacture of a human rhinovirus Type 16 challenge stock. MLS manufactured the rhinovirus challenge stock under contract and according to the appropriate current Good Manufacturing Procedures (cGMPs) for use in early-phase human clinical trials while simultaneously meeting the desired titer specifications under aggressive timelines.

Challenge stocks are wild type, native viruses that are fully capable of causing disease in the target population. These virus preparations are designed to be used in conjunction with clinical trials testing the efficacy of a given therapeutic. A challenge stock of infectious virus permits infection of a group of healthy volunteers where the precise viral dose, timing and progression of disease can be monitored. In turn, administration of the anti-viral therapeutic or vaccine may be tested at varying times and doses to better understand the efficacy of the drug in a controlled environment. Beyond the advantages of providing a carefully monitored test environment, the use of a challenge stock in designing an efficacy study is the increased efficiency in patient enrollment, and time to completion of the study. In clinical efficacy trials that depend on the identification of randomly infected individuals for inclusion in the study, it is common to encounter long delays and difficulties with identification of appropriate test subjects. Studies utilizing challenge stocks such as the human rhinovirus permit rapid enrollment and testing of the therapeutic resulting in significant cost savings along the road to commercialization.

Victor Van Cleave, Ph.D., Vice President of Research and Development (R&D) at Meridian Life Science, stated, “MLS is pleased to have been selected for the cGMP manufacture of a human rhinovirus Type 16 challenge stock. This project, similar to other challenge stocks and vaccines we’ve produced, was an excellent fit for MLS’ core virology and virus-based product manufacturing capabilities. The contract manufacturing process required successful technology transfer and development of a scalable production process to make this challenge stock. MLS and our scientists are proud to be a part of this drug development effort that could significantly reduce the incidence and/or severity of rhinovirus infections.”

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs